CTI BioPharma Corp.
CTIC

$1.2 B
Marketcap
$9.10
Share price
Country
$0.01
Change (1 day)
$9.10
Year High
$4.01
Year Low
Categories

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

marketcap

Earnings for CTI BioPharma Corp. (CTIC)

Earnings in 2022 (TTM): $-92,992,000

According to CTI BioPharma Corp.'s latest financial reports the company's current earnings (TTM) are $-92,992,000. The earnings displayed on this page is the company's Pretax Income.

Earnings history of CTI BioPharma Corp.

Annual Earnings

Year Income Before Tax Net Income
2022 $-92,992,000 $-91,041,000
2021 $-97,908,000 $-99,636,000
2020 $-52,451,000 $-52,951,000
2019 $-40,023,000 $-42,317,000
2018 $-29,352,000 $-29,320,000
2017 $-40,831,000 $-40,670,000
2016 $-52,953,000 $-52,009,000
2015 $-120,763,000 $-119,422,000
2014 $-94,229,000 $-93,367,000
2013 $-43,550,000 $-42,743,000
2012 $-101,687,000 $-101,374,000
2011 $-62,619,000 $-62,360,000
2010 $-95,395,000 $-82,642,000
2009 $-95,395,000 $-95,395,000
2008 $-180,029,000 $-180,029,000
2007 $-138,108,000 $-138,108,000
2006 $-135,819,000 $-135,819,000
2005 $-102,505,000 $-102,505,000
2004 $-252,298,000 $-252,298,000
2003 $-130,031,000 $-130,031,000
2002 $-49,903,000 $-49,903,000
2001 $-74,285,000 $-80,273,000
2000 $-51,384,503 $-51,928,791
1999 $-35,700,000 $-36,300,000
1998 $-24,600,000 $-25,000,000
1997 $-22,700,000 $-23,000,000
1996 $-13,400,000 $-13,900,000